Malic Acid

Malic Acid

SCHEMBL672695

O=C(O)CC(O)C(=O)O.[CaH2].[CaH2]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F

The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.94
SLC22A6 Q4U2R8 1/20 0.53
TET2 Q6N021 6/20 0.52
TET3 O43151 2/20 0.52
TET1 Q8NFU7 1/20 0.52
KDM4A O75164 2/20 0.50
KDM4C Q9H3R0 2/20 0.50
KDM2A Q9Y2K7 2/20 0.50
OR51E2 Q9H255 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
GABRR1 P24046 2/20 0.43
LMNA P02545 1/20 0.43
KMO O15229 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Malic Acid SCHEMBL27973243 1.00 SMN1; SMN2 (0.94) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL1577946 1.00 SMN1; SMN2 (0.94) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL9239583 0.97 SMN1; SMN2 (0.88) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL2179596 0.97 SMN1; SMN2 (0.88) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL29152423 0.97 SMN1; SMN2 (0.88) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL18684900 0.97 SMN1; SMN2 (0.88) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL9166463 0.97 SMN1; SMN2 (0.88) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL29152415 0.97 SMN1; SMN2 (0.88) SMN1; SMN2SLC22A6TET2TET3TET1
Malic Acid SCHEMBL856 0.97
Malic Acid SCHEMBL14125844 0.97 SMN1; SMN2 (1.00) SMN1; SMN2SLC22A6TET2TET3TET1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4521952-A1 REACTIVE GRANULATION OF CALCIUM CITRATE MALATE, DICALCIUM MALATE, AND DIMAGNESIUM MALATE Balchem Corporation (US) 2025-03-19 EP claimed
WO-2023220606-A1 REACTIVE GRANULATION OF CALCIUM CITRATE MALATE, DICALCIUM MALATE, AND DIMAGNESIUM MALATE BALCHEM CORPORATION (US) 2023-11-16 WO claimed
US-20230357280-A1 REACTIVE GRANULATION OF CALCIUM CITRATE MALATE, DICALCIUM MALATE, AND DIMAGNESIUM MALATE BALCHEM CORPORATION 2023-11-09 US claimed
US-11534458-B2 Phosphorus-sparing nutritional composition ALBION LABORATORIES, INC. (US) 2022-12-27 US claimed
CN-113678979-A Solid beverage for promoting synthesis and secretion of insulin of type II diabetes mellitus people 上海英库商务咨询有限公司 2021-11-23 CN claimed
US-20210299169-A1 Galectin-3 Governs and Coordinates ESCRT and Autophagic Responses During Endomembrane Damage UNM RAINFOREST INNOVATIONS 2021-09-30 US claimed
US-20210137975-A1 PHOSPHORUS-SPARING NUTRITIONAL COMPOSITION JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT 2021-05-13 US claimed
US-10912796-B2 Phosphorus-sparing nutritional composition ALBION LABORATORIES, INC. (US) 2021-02-09 US claimed
EP-3733172-A1 BUFFERED UPPER GI ABSORPTION PROMOTER Albion Laboratories, Inc. (US) 2020-11-04 EP claimed
EP-2758056-B1 BUFFERED UPPER GI ABSORPTION PROMOTER ALBION LABORATORIES INC (US) 2020-06-24 EP claimed
US-20160015746-A1 PHOSPHORUS-SPARING NUTRITIONAL COMPOSITION JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT 2016-01-21 US claimed
EP-2967117-A1 PHOSPHORUS-SPARING NUTRITIONAL COMPOSITION AMIP, LLC (US) 2016-01-20 EP claimed
WO-2015113997-A1 PROCESS FOR PRODUCING CALCIUM FORTIFIED FERMENTED DAIRY COMPOSITIONS COMPAGNIE GERVAIS DANONE (FR) 2015-08-06 WO claimed
WO-2015114397-A1 PROCESS FOR PRODUCING A FORTIFIED COMPOSITION COMPAGNIE GERVAIS DANONE (FR) 2015-08-06 WO claimed
WO-2014159886-A1 PHOSPHORUS-SPARING NUTRITIONAL COMPOSITION AMIP, LLC (US) 2014-10-02 WO claimed
US-8202546-B2 Nutritional supplement for use under physiologically stressful conditions VERTICAL PHARMACEUTICALS, INC. (US) 2012-06-19 US claimed
US-20100136104-A1 NUTRITIONAL SUPPLEMENT FOR USE UNDER PHYSIOLOGICALLY STRESSFUL CONDITIONS CIBC BANK USA 2010-06-03 US claimed
US-20090035385-A1 COMPOSITIONS INCLUDING IRON DRUGTECH CORPORATION (US) 2009-02-05 US claimed
EP-4521952-A4 REACTIVE GRANULATION OF CALCIUM CITRATE MALATE, DICALCIUM MALATE, AND DIMAGNESIUM MALATE BALCHEM CORP (US) 2025-10-08 EP disclosed
US-20070227399-A1 COMPOSITIONS AND METHODS FOR THE PRESERVATION OF WOOD NOVUS INTERNATIONAL INC. (US) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11534458-B2 Phosphorus-sparing nutritional composition PHPT1, PPA1, PTH1R SMN1; SMN2 1232/4885SLC22A6 662/4885TET2 1796/4885
US-20210137975-A1 PHOSPHORUS-SPARING NUTRITIONAL COMPOSITION PHPT1, PPA1, PTH1R SMN1; SMN2 1232/4885SLC22A6 662/4885TET2 1796/4885
US-20160015746-A1 PHOSPHORUS-SPARING NUTRITIONAL COMPOSITION PHPT1, PPA1, PTH1R SMN1; SMN2 1232/4885SLC22A6 662/4885TET2 1796/4885
US-10912796-B2 Phosphorus-sparing nutritional composition PHPT1, PPA1, PTH1R SMN1; SMN2 1232/4885SLC22A6 662/4885TET2 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.